Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.